
Gilead and Jounce Therapeutics have come together in a new immuno-oncology partnership potentially worth over $700 million. The primary drive …

Celgene has entered into a collaboration with Jounce Therapeutics that will see the pair jointly develop and commercialise Jounce’s lead …

